Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics
In 2022, AROCELL AB has already paid €1.55 in dividends. The last payout was in October 2022.

Financials

In the last quarter, AROCELL AB had revenue of €910.3k and net profit of -€1.34m
(EUR) June 2025
YoY
Revenue 910.3k -
Gross profit -14.81k -
Net profit -1.34m -
EBITDA -414.27k -

Fundamentals

Metric Value
Market capitalization
€11.9m
Number of shares
230.36m
52-week high/low
€0.0594 - €0.0311
Dividends No
Beta
1.21
P/E ratio
4.58
PEG ratio
0.00
P/B ratio
0.49
P/S ratio
1.23

Company profile

AroCell AB (publ), a vitro diagnostics company, focuses on monitoring of hematological malignancies, breast cancer, and other solid tumors. The company develops, manufactures, and sells AroCell TK 210 ELISA, an immunoassay kit for the determination of Thymidine Kinase 1 in human blood. It also offers TUBEX TF, a bacteriological rapid test for diagnosis of typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was incorporated in 2000 and is based in Uppsala, Sweden.

Name
AROCELL AB
CEO
Anders Hultman
Headquarters Uppsala,
Sweden
Website
Sector
Utilities
IPO
28/07/2000
Employees 22

Ticker symbols

Exchange Symbol
Sto
AROC.ST
Frankfurt
80R.F
Stockholm
AROC.ST
🍪

Parqet  uses cookies. Learn more